The Alzheimer's Drug Discovery Foundation (ADDF) announced on October 28, 2026 that Eli Lilly and Company has licensed SpeechDx, a longitudinal speech-and-biomarker dataset built by the foundation's Diagnostics Accelerator, and will use the resource to study whether speech can serve as a tool for Alzheimer's research. Lilly is the third organization to license the dataset, joining Siemens Healthineers and Callyope. The foundation characterizes SpeechDx as the largest harmonized longitudinal…
This article has been indexed from Unite.AI
Read the original article:
Eli Lilly Licenses ADDF’s SpeechDx Dataset for Alzheimer’s Research